If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Spain to keep using AstraZeneca vaccine, no blood clot cases reported

Thu, 11th Mar 2021 12:55

(Adds latest data, government comment on AstraZeneca vaccine)

By Inti Landauro and Joan Faus

MADRID, March 11 (Reuters) - Spain has registered no cases
of blood clots related to AstraZeneca's COVID-19 vaccine
so far and will continue administering the shot, Health Minister
Carolina Darias said on Thursday.

She spoke shortly after Danish health authorities suspended
using the vaccine produced by Anglo-Swedish firm AstraZeneca
after several cases of blood clots, including one death.

Darias told La Sexta TV that minor side-effects from the
shot had been reported in Spain and that she was aware of cases
of blood clots in Austria, but "so far, no causal relation
between the vaccine and the blood clot events has been
established".

Europe's EMA drug regulator subsequently backed the vaccine,
saying its benefits outweighed the risks.

Spain, which has only approved the shot for 18- to 55-year-
olds, said it would wait for more data from the EMA before
considering whether to follow other European countries and
broaden the age range.

Infections have fallen to their lowest since August after
retreating rapidly from a third wave that peaked in January, but
the rate of decline is slowing.

As measured over the past 14 days the number of cases per
100,000 people reached 132 on Thursday, edging down from 134 the
day before.

The government reported 6,255 new infections, bringing the
total to nearly 3.2 million, while deaths increased by 166 to
72,085.

With transmission falling and the vaccine roll-out gathering
pace, some regions are lifting restrictions.

From March 15, Catalonia will allow non-essential small
shops to open at weekends and let people who live together move
freely within the region. Residents are currently confined to
their county except for work or health reasons.

With an average of 170 cases per 100,00 people in the past
14 days, Catalonia has one of Spain's highest infection rates.

During two upcoming holiday weekends all mainland Spanish
regions apart from Madrid have agreed to ban non-essential
travel across their borders to prevent a resurgence.
(Reporting by Inti Landauro, Joan Faus and Nathan Allen;
Editing by Andrei Khalip, Mark Heinrich and Giles Elgood)

More News
Today 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
Today 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.